I reported previously (Mar 2014) about hCDR1 from Israeli biotech XTL for treating Lupus (Systemic Lupus Erythematosus – SLE). Trials have found many cases where low dosages of hCDR1 are more effective than high ones. XTL have filed new US and European patents.

http://www.prnewswire.com/news-releases/xtl-biopharmaceuticals-announces-new-patent-filing-in-us-for-lupus-drug-hcdr1-589846971.html

http://lupusnewstoday.com/2016/09/08/xtl-biopharmaceuticals-granted-european-union-patent-for-lupus-drug-hcdr1